Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes (MT2D)
Mathematical Modeling of Type 2 Diabetes Mellitus
This observational study aims to collect detailed metabolic and physiologic data from adults with insulin-dependent type 2 diabetes mellitus following consumption of a mixed meal tolerance test. Participants will undergo frequent blood sampling over a 4-hour period after consuming a standardized liquid mixed meal to measure glucose, insulin, glucagon, C-peptide, and triglyceride responses. Participants will also use continuous glucose monitoring and wearable physical activity tracking devices during free-living conditions.
The purpose of this study is to develop mathematical models and digital representations ("digital twins") of people with type 2 diabetes mellitus. These models may help researchers better understand metabolic responses to meals, physical activity, and diabetes treatments, and may support future development of personalized diabetes technologies and therapies.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Participants will first complete a screening visit at the Clinical Nutrition Research Center (CNRC) at the Illinois Institute of Technology. Screening procedures include assessment of medical history, dietary habits, physical activity history, body measurements, vital signs, glycated hemoglobin (HbA1c), and evaluation of eligibility criteria. Eligible participants will receive a continuous glucose monitor (CGM) and wearable activity tracker and will complete dietary recall assessments during the outpatient monitoring period.
Participants will undergo approximately 8 days of outpatient monitoring using continuous glucose monitoring and wearable physical activity tracking devices during free-living conditions. During this period, participants will continue their usual diabetes management and daily activities while recording dietary intake and medication use.
Participants will then complete an in-clinic Liquid Meal Test (LMT) visit following an overnight fast. During the study-day visit, an indwelling intravenous catheter will be placed for repeated venous blood collection. Blood samples will be collected before and over a 4-hour period after consumption of a standardized liquid meal consisting of vanilla-flavored Ensure®. Plasma measurements will include glucose, insulin, glucagon, C-peptide, and triglycerides. Participants will remain seated and monitored throughout the study visit, and safety assessments will be performed before discharge.
The information collected from continuous glucose monitoring, wearable activity tracking, dietary assessments, and repeated blood sampling will be used to develop mathematical models capable of simulating physiologic and metabolic responses in individuals with insulin-dependent type 2 diabetes mellitus. These models may contribute to future research focused on personalized diabetes management, optimization of therapeutic strategies, and evaluation of diabetes technologies.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Chelsea Preiss, Clinical Research Manager, MS
- Numéro de téléphone: 312-567-5300
- E-mail: cpreiss@illinoistech.edu
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60616
- Recrutement
- Illinois Institute of Technology
-
Contact:
- Chelsea Preiss, MS
- Numéro de téléphone: 312-567-5300
- E-mail: cpreiss@illinoistech.edu
-
Chercheur principal:
- Indika Edirisinghe, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Men or women, 18-65 years of age
- Diagnosed with insulin-dependent type 2 diabetes mellitus HbA1c ≥ 6.5% at screening
- Current insulin therapy for ≥ 6 months prior to screening
- Nonsmokers (past smokers can be allowed if they have abstained for a minimum of 12 months)
- Judged to be in good health based on medical history (i.e., no clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal, or hepatic disease)
- Able to provide informed consent
- Able to comply with and perform the procedures requested by the protocol (including dietary restrictions, consumption of study foods, records of food diary, sample collection procedures, and study visit schedule)
Exclusion Criteria:
- Men and women with known or suspected intolerance, allergies, or hypersensitivity to study foods
- Men and women with low hemoglobin (Hgb) levels below 9.5 g/dL at the screening visit, indicating anemia
- Men and women with blood pressure >160 mmHg (systolic) / 100 mmHg (diastolic) at the screening visit
- Women who are pregnant or planning to become pregnant during the study
- Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI.
- Vegan or other extreme dietary regimens (e.g., Atkins diet, etc.) as judged by the investigator
- History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional
- Donated blood within the last 3 months
- Unstable weight: gained or lost weight +/- 5 kg (11 lbs) in previous 2 months
- Unusual working hours i.e., working overnight (e.g. 3rd shift)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Adults With Insulin-Dependent Type 2 Diabetes Mellitus
Adults 18 to 65 years of age with insulin-dependent type 2 diabetes mellitus who will undergo a liquid meal tolerance test with frequent blood sampling over 4 hours following consumption of a standardized liquid meal.
Participants will also undergo outpatient continuous glucose monitoring and wearable physical activity tracking during free-living conditions to support mathematical modeling of metabolic and physiologic responses.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Plasma Glucose Concentration (mg/dL)
Délai: -10 to 240 minutes relative to meal consumption
|
Plasma glucose concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox).
Unit of Measure: mg/dL
|
-10 to 240 minutes relative to meal consumption
|
|
Change in Plasma Insulin Concentration (µIU/mL)
Délai: -10 to 240 minutes relative to meal consumption
|
Plasma insulin concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox).
Unit of Measure: (µIU/mL)
|
-10 to 240 minutes relative to meal consumption
|
|
Change in Plasma Glucagon Concentration (pg/mL)
Délai: -10 to 240 minutes relative to meal consumption
|
Plasma glucagon concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a multiplex immunoassay platform (Luminex).
Unit of Measure: pg/mL
|
-10 to 240 minutes relative to meal consumption
|
|
Change in Plasma C-Peptide Concentration (ng/mL)
Délai: -10 to 240 minutes relative to meal consumption
|
Plasma C-peptide concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a multiplex immunoassay platform (Luminex). Unit of Measure: ng/mL |
-10 to 240 minutes relative to meal consumption
|
|
Change in Plasma Triglyceride Concentration (mg/dL)
Délai: -10 to 240 minutes relative to meal consumption
|
Plasma triglyceride concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox). Unit of Measure: mg/dL |
-10 to 240 minutes relative to meal consumption
|
|
Continuous Glucose Monitoring Metrics During Free-Living Conditions
Délai: Approximately 8 days during outpatient monitoring
|
Interstitial Glucose Concentration during Free-Living Conditions via Continuous Glucose Monitor Description: Interstitial glucose concentration measured continuously during outpatient free-living conditions using the Dexcom G7 continuous glucose monitoring device. Unit of Measure: mg/dL |
Approximately 8 days during outpatient monitoring
|
|
Average Daily Step Count (steps/day)
Délai: Approximately 8 days during outpatient monitoring.
|
Average daily step count, reported in steps per day, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
|
Approximately 8 days during outpatient monitoring.
|
|
Average Daily Active Minutes (minutes/day)
Délai: Approximately 8 days during outpatient monitoring.
|
Average daily active minutes, reported in minutes per day, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
|
Approximately 8 days during outpatient monitoring.
|
|
Average Daily Sleep Duration (hours/night)
Délai: Approximately 8 days during outpatient monitoring.
|
Average sleep duration, reported in hours per night, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
|
Approximately 8 days during outpatient monitoring.
|
|
Average Resting Heart Rate (beats/minute)
Délai: Approximately 8 days during outpatient monitoring.
|
Average resting heart rate, reported in beats per minute (bpm), measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
|
Approximately 8 days during outpatient monitoring.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dietary Intake Assessment Using ASA24 Dietary Recall
Délai: Approximately 8 days during outpatient monitoring
|
To assess dietary intake and nutritional patterns using self-reported ASA24 dietary recall assessments during the outpatient monitoring period.
|
Approximately 8 days during outpatient monitoring
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Indika Edirisinghe, Ph.D, Illinois Institute of Technology
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB-2026-33
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .